Compile Data Set for Download or QSAR
Report error Found 240 of ic50 data for polymerid = 747
TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM420028(US10487083, Example B)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505104(US11066406, A)
Affinity DataIC50: 0.200nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505105(US11066406, B)
Affinity DataIC50: 0.200nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493068(US10981911, Example 9 | 2-((1r,4r)-4-(2-(1H-1,2,4-...)
Affinity DataIC50: 0.300nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493101(US10981911, Example 41 | 2-((1r,4r)-4-(2-(Thiazol-...)
Affinity DataIC50: 0.400nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493067(US10981911, Example 8 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 0.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50434787(CHEMBL2386635 | US10703751, Example 644 of WO20110...)
Affinity DataIC50: 0.600nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493066(US10981911, Example 7 | 2-(1-((1r,4r)-4-(Cyanometh...)
Affinity DataIC50: 0.600nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493156(US10981911, Example 95 | (EZ)—N-((1-((1r,4r)-...)
Affinity DataIC50: 0.600nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505106(US11066406, C)
Affinity DataIC50: 0.600nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493070(US10981911, Example 11 | 2-((1r,4r)-4-(2-(Oxazol-4...)
Affinity DataIC50: 0.800nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493096(US10981911, Example 36 | N-((1H-imidazol-2-yl)meth...)
Affinity DataIC50: 0.800nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387819(US10294226, Compound Ex. 2 | 2-((1r,4r)-4-(2-(1H-I...)
Affinity DataIC50: 1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493100(US10981911, Example 40 | 1-((1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505108(US11066406, Ex. 2)
Affinity DataIC50: 1nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493075(US10981911, Example 16 | 2-((1r,4r)-4-(2-(2H-1,2,3...)
Affinity DataIC50: 1.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493076(US10981911, Example 17A | (E)-N-((1-((1r,4r)-4-(Cy...)
Affinity DataIC50: 1.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493080(US10981911, Example 20 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 1.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493081(US10981911, Example 21 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 1.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493092(US10981911, Example 32 | N-((3R,5R)-Adamantan-1-yl...)
Affinity DataIC50: 1.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387823(US10294226, Compound Ex. 6 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387823(US10294226, Compound Ex. 6 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493083(US10981911, Example 23 | N-(4-Cyanobicyclo[2.2.1]h...)
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527409(CHEMBL4447497 | US10981911, Example 58)
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505112(US11066406, Ex. 6)
Affinity DataIC50: 1.40nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387828(US10294226, Compound Ex. 11 | 2-(1-((1r,4r)-4-(Cya...)
Affinity DataIC50: 1.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387828(US10294226, Compound Ex. 11 | 2-(1-((1r,4r)-4-(Cya...)
Affinity DataIC50: 1.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505117(US11066406, Ex. 11)
Affinity DataIC50: 1.60nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493112(US10981911, Example 52 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 1.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493120(US10981911, Example 60 | 2-((1r,4r)-4-(2-(1H-Pyraz...)
Affinity DataIC50: 1.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493073(US10981911, Example 14 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 1.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493116(US10981911, Example 56 | 2-((1r,4r)-4-(2-(1H-Imida...)
Affinity DataIC50: 1.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493281(US10981911, Example 201 | 2-(1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 1.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387822(US10294226, Compound Ex. 5 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 2.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387822(US10294226, Compound Ex. 5 | 2-(1-((1r,4r)-4-(Cyan...)
Affinity DataIC50: 2.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493114(US10981911, Example 54 | 4-(2-(1-((1r,4r)-4-(Cyano...)
Affinity DataIC50: 2.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527404(CHEMBL4514898 | US10981911, Example 62)
Affinity DataIC50: 2.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493140(US10981911, Example 80 | 1-((1r,4r)-4-(Cyanomethyl...)
Affinity DataIC50: 2.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493269(US10981911, Example 198 | 2-(1-((1r,4r)-4-(Cyanome...)
Affinity DataIC50: 2.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM505111(US11066406, Ex. 5)
Affinity DataIC50: 2.10nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493123(US10981911, Example 63 | 2-((1r,4r)-4-(2-(2H-Tetra...)
Affinity DataIC50: 2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50527407(CHEMBL4582390 | US10981911, Example 33)
Affinity DataIC50: 2.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493107(US10981911, Example 47 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 2.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493079(US10981911, Example 19 | N-((1r,4r)-4-(Cyanomethyl...)
Affinity DataIC50: 2.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493088(US10981911, Example 28 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 2.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493126(US10981911, Example 66 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 2.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM493087(US10981911, Example 27 | 2-(1-((1r,4r)-4-(Cyanomet...)
Affinity DataIC50: 2.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387827(US10294226, Compound Ex. 10 | N-(4-(Cyanomethyl)bi...)
Affinity DataIC50: 2.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

Displayed 1 to 50 (of 240 total ) | Next | Last >>
Jump to: